Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

RLYB vs MXCT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

RLYB Captures Overall Composite Edge (63.0 BUY vs 41.7 SELL), While MXCT Leads 4–0 on Growth & Valuation Pillars

RLYB Overall Winner 6-Pillar Tally: RLYB 0 – 4 MXCT (2 Tie) Matrix Metrics: RLYB 6 – 3 MXCT

As of Nov 20, 2026, Rallybio Corporation (RLYB) captures the overall head-to-head institutional edge over MaxCyte, Inc. (MXCT) on higher Unified Composite conviction (63.0/100 BUY vs. 41.7/100 SELL) after splitting the core matrix 6–3 (led by composite factor balance), while MXCT wins 4–0 across the 6-pillar growth and valuation breakdown. RLYB trades at $15.47 (N/M Forward P/E, -5050.9% operating margin) versus MXCT at $1.37 (N/M Forward P/E, -85.5% operating margin).

  • Growth vs. Quality Trade-Off: RLYB earns the overall head-to-head edge with a stronger Unified Composite Score (63.0/100 BUY vs. MXCT 41.7/100 SELL) and 0.37β · 24% Vol risk profile, whereas MXCT leads top-line expansion (+48.7% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: RLYB is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.9); meanwhile MXCT trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 55.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About RLYB vs MXCT
RLYB NASDAQ Head-to-Head Winner
Rallybio Corporation Common Stock
Pharmaceutical Preparations
$15.47
-0.32% 1D
Market Cap $86.9M
TTM Revenue $434,000
Forward P/E N/M
Beta / 30D Vol 0.37β · 24% Vol
Unified Composite Score
63.0 / 100 BUY
Tech 81.0 Fund 63.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -2.7%), weak momentum, RSI 40
RSI-14: 39.9 · SMA20: $15.70 · SMA50: $16.38
MXCT NASDAQ
MaxCyte, Inc. Common Stock
Services-Commercial Physical & Biological Research
$1.37
+7.03% 1D
Market Cap $132.2M
TTM Revenue $34M
Forward P/E N/M
Beta / 30D Vol 1.19β · 96% Vol
Unified Composite Score
41.7 / 100 SELL
Tech 46.0 Fund 52.0 Flow 62.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (2.1% over 20 days), RSI 55
RSI-14: 55.3 · SMA20: $1.36 · SMA50: $1.25

6-Pillar Scorecard Institutional Category Breakdown (RLYB 0 – 4 MXCT)

Columns: Metric · RLYB · MXCT
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E 3.4x N/M
PEG Ratio N/M N/M
EV / Revenue 105.5x 3.9x
2. Growth & Scale MXCT
Revenue Growth (YoY) +0.0% +48.7%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $434,000 $34M
Market Cap $86.9M $132.2M
3. Profitability & Quality MXCT
Gross Margin N/A 81.0%
Operating Margin -5050.9% -85.5%
Net Profit Margin 6177.4% -81.4%
Return on Equity (ROE) 34.5% -16.9%
4. Balance Sheet & Cash Flow MXCT
Cash Generation (TTM) -$28M -$24M
Cash Flow Margin N/A -69.2%
Net Cash / Leverage $41M Net Cash $2.2M Net Debt (0.11x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MXCT
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: RLYB (6) vs MXCT (3)
Institutional Metric RLYB MXCT Criterion Row Edge
Market Capitalization
Scale
$86.9M $132.2M Larger Scale MXCT
Trailing P/E Ratio
Valuation
3.4x N/M Lower Multiple RLYB
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +48.7% Higher Growth MXCT
Operating Margin (TTM)
Profitability
-5050.9% -85.5% Higher Margin MXCT
Net Profit Margin
Profitability
6177.4% -81.4% Higher Margin RLYB
Return on Equity (ROE)
Capital Efficiency
34.5% -16.9% Higher ROE RLYB
52-Week Range Position
Momentum
88% ($1–$18) 63% ($1–$2) Stronger Trend RLYB
Beta / 30D Volatility
Risk Regime
0.37β · 24% Vol 1.19β · 96% Vol Lower Realized Risk RLYB
Unified Institutional Score
Composite Signal
63.0 / 100 (BUY) 41.7 / 100 (SELL) Higher Composite RLYB
Trailing 12M Revenue (USD)
Operating Scale
$434,000 $34M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 81.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 105.5x EV/Rev N/M PEG · 3.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$28M ($41M Net Cash) -$24M ($2.2M Net Debt (0.11x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MXCT +1.47 pp
RLYB: -5.67% · MXCT: -4.2%
3M Horizon MXCT +6.48 pp
RLYB: -7.92% · MXCT: -1.44%
6M Horizon MXCT +34.31 pp
RLYB: -2.58% · MXCT: +31.73%
1Y Horizon RLYB +2397.78 pp
RLYB: +2378.37% · MXCT: -19.41%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period RLYB Revenue MXCT Revenue RLYB Op. Margin MXCT Op. Margin Margin Leader
FY2019 N/A $10M N/A -93.7% MXCT
FY2020 N/A $20M N/A -71.6% MXCT
FY2021 N/A $20M N/A -84.3% MXCT
FY2022 N/A $30M N/A -95.2% MXCT
FY2023 N/A $20M N/A -247.7% MXCT
FY2024 $0M $20M -9511.9% -230.5% MXCT
FY2025 $0M $20M -3853.6% -247.6% MXCT

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
RLYB UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact RLYB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MXCT UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact MXCT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
RLYB Moat Profile Scale & Operating Efficiency Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $86.9M market capitalization and -5050.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
MXCT Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $132.2M market capitalization and -85.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ RLYB vs MXCT Key Questions & Quantitative Answers

As of Nov 20, 2026, Rallybio Corporation (RLYB) captures the overall head-to-head institutional edge over MaxCyte, Inc. (MXCT) on higher Unified Composite conviction (63.0/100 BUY vs. 41.7/100 SELL) after splitting the core matrix 6–3 (led by composite factor balance), while MXCT wins 4–0 across the 6-pillar growth and valuation breakdown. RLYB trades at $15.47 (N/M Forward P/E, -5050.9% operating margin) versus MXCT at $1.37 (N/M Forward P/E, -85.5% operating margin). Growth vs. Quality Trade-Off: RLYB earns the overall head-to-head edge with a stronger Unified Composite Score (63.0/100 BUY vs. MXCT 41.7/100 SELL) and 0.37β · 24% Vol risk profile, whereas MXCT leads top-line expansion (+48.7% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: RLYB is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.9); meanwhile MXCT trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 55.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MXCT leads the Growth & Scale pillar: RLYB posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on $434,000 TTM revenue (N/A gross margin, -5050.9% operating margin), compared with MXCT at +48.7% YoY revenue growth and +0.0% YoY earnings growth on $34M TTM revenue (81.0% gross margin, -85.5% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), RLYB cumulative revenue shifted N/A while MXCT shifted +100.0%. In operating R&D and SG&A reinvestment, RLYB deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MXCT.

RLYB and MXCT trade at balanced relative valuation multiples. RLYB trades at N/M Forward P/E, 3.4x Trailing P/E, N/M PEG, and 105.5x EV/Revenue (unreported FCF margin), whereas MXCT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.9x EV/Revenue (-69.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RLYB (34.5% ROE) versus MXCT (-16.9% ROE) capital efficiency.

In options market volatility and institutional positioning, RLYB carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.37β · 24% Vol realized risk). By comparison, MXCT carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.19β · 96% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.